Pamela M. Klein

Pamela Klein serves as an Independent Director on the Board of Directors for multiple companies, including argenx since 2016, Frontier Medicines, ONA Therapeutics, and Shasqi in 2023. In addition, Pamela Klein holds positions as Venture Partner at Ysios Capital and Independent Director at Patrys Limited. With extensive experience in oncology drug development and strategy as an Independent Biotech/Pharma Consultant since 2008, Pamela Klein also acted as Interim Chairperson for I-Mab Biopharma from 2020 to 2024 and served on the Board of Directors for F-star Therapeutics, Inc. until March 2023. Pamela Klein holds an M.D. in Oncology and Internal Medicine from Loyola University Chicago Stritch School of Medicine and a Bachelor's degree in Biology from California State University, Northridge.